S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial

Table 2 Survival outcomes

	Intention to treat population			Per-protocol population
	SOX	CapeOX	Effect size (95% CI); p value	SOX	CapeOX	Effect size (95% CI), p value
Number of patients	168	172		164	161
Median PFS	7.1 (6.4-8.1)	6.3 (4.9-6.7)	0.83 (0.66-1.04), p = .10	6.9 (6.4-7.9)	6.3 (5.2-6.7)	0.84 (0.67-1.06), p = .13
Median OS	19.0 (15.3-23.0)	18.5 (14.1-20.8)	0.86 (0.68-1.08), p = .19	19.1 (15.0-23.0)	17.6 (14.1-20.5)	0.85 (0.67-1.08), p = .17
Number of patients	150	151		147	145
Median PPS	9.3 (6.7-11.6)	9.5 (7.4-12.1)	0.97 (0.76-1.23), p = .81	9.3 (6.9-11.6)	9.6 (7.4-12.1)	0.96 (0.75-1.23), p = .75

Data are represented as n (%), time in months (95% CI) or effect size (95% CI). SOX, S-1 plus oxaliplatin; CapeOX, Capecitabine plus oxaliplatin; PFS, progression-free survival; PPS, post-progression survival, OS = overall survival.

ISSN: 1471-2407